RenovoRx, Inc. announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also highlighted in the video series is the Company's multi-center TIGeR-PaC Phase 3 clinical trial in locally advanced pancreatic cancer.

Viewers will be introduced to the Company's CEO, Shaun Bagai, in the first video in the series. Additional segments to be released in the coming weeks. TIGeR-PaC is a randomized multi-center Phase 3 study using RenovoRx's innovative therapy platform, RenovoTAMP (RenovoRx Trans-arterial Micro-perfusion).

The study is evaluating the Company's first product candidate, RenovoGem, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.